Beata Matyjaszek‐Matuszek

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

2023 Guidelines on the management of patients with diabetes - a position of Diabetes Poland

Aleksandra Araszkiewicz, Elżbieta Bandurska‐Stankiewicz, Sebastian Borys et al. · Current Topics in Diabetes · 2023 · 62 citations · Full text

Metabolic Syndrome, Diabetes Management, Health Policy +7

Featured paper Clinical implications of vitamin D deficiency

Beata Matyjaszek‐Matuszek, Monika Lenart-Lipińska, Ewa Woźniakowska · Menopausal Review · 2015 · 51 citations · Full text

Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin

Juan P. Frías, Alan Wynne, Beata Matyjaszek‐Matuszek et al. · Diabetes Obesity and Metabolism · 2019 · 43 citations

Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up

Monika Lenart-Lipińska, Beata Matyjaszek‐Matuszek, Wojciech Gernand et al. · Diabetes Research and Clinical Practice · 2013 · 42 citations

Metabolic Syndrome, Fibrosis, Short-term Follow-up +12